Portfolio Lab

Gossamer Bio, Inc.

  • Stock
  • Ticker GOSS
  • ISIN US38341P2011
  • Nasdaq

Health care · Pharmaceuticals · USA

$10.72 −4.54%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Gossamer Bio, Inc. since 02/2019, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

GOSSGlobal equities (VT)

$10,000 grew to $108. Global equities (VT): $14,653.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −99.6% in 10/2026, measured from the peak in 12/2019. The old peak has not been reached again yet.

1-year return
−95.7%
5-year return p.a.
−59.0%
Return p.a. since 02/2019
−46.7%
Volatility p.a.
85.2%
Largest decline
−99.6%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue9.49.9111314179.238
Operating income-36-37-39-49-46-45-267.2
EBITDA-36-37-39-49-46-45-267.2
Net income-33-37-38-48-47-4717-48
Earnings per share-0.15-0.16-0.17-16.9242.58-0.20-0.08-7.36
Balance sheet
Total assets3152812412091721297764
Liabilities286287287291295290171187
Equity29-6.3-46-82-123-161-94-123
Cash4629268.938414151
Long-term debt0.0–––––––
Cash flow
Operating cash flow-35-40-47-36-48-39-39-30
Capital expenditure0.00.0-0.10.00.00.00.00.0
Free cash flow-35-40-47-36-48-39-39-30

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2025 at +242.7%, weakest 2022 at −80.8%. 2 of 6 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
10 Nov 2026−$7.36
13 Aug 2026−$0.08
15 May 2026−$0.20
17 Mar 2026$42.58
5 Nov 2025−$16.92
5 Aug 2025−$0.17
15 May 2025−$0.16
13 Mar 2025−$0.15
7 Nov 2024−$0.14
12 Aug 2024$0.22
7 May 2024−$0.19
5 Mar 2024−$0.15

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€59m
Market cap in trading currency
$65.6m
Enterprise value
$14.4m
P/E
0.3
P/S
0.84
P/B
–
EV/Sales
0.18
EV/EBITDA
–
Earnings yield
325.9%
FCF yield
-238.0%

Results (last four quarters)

Revenue
$78.4m
Gross profit
–
EBITDA
−$110m
Net income
−$125m
Earnings per share
$34.94
Revenue per share
$12.82
Revenue growth
+189.1%
Earnings growth
–

Profitability

Gross margin
–
Operating margin
-140.0%
Net margin
-159.5%
Return on equity
–
Return on assets
-194.4%

Balance sheet and cash flow

Cash
$51.2m
Cash per share
$8.37
Financial debt
–
Debt/equity %
–
Current ratio
0.60
Book value per share
−$20.08
Operating cash flow
−$156m
Free cash flow
−$156m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
6.12m
Volume
191,353
Avg. volume 3 months
261,624
Relative volume
0.8

Price and technicals

Price
$10.72
1 day
−4.5%
52-week high
$303.20
52-week low
$8.43
Distance to 52-week high
−96.5%
Distance to 52-week low
+27.2%
Distance to 50-day line
+3.0%
Distance to 200-day line
−59.7%
RSI (14)
51
Volatility 1M
80.4%

Performance

1 week
−2.3%
1 month
+13.3%
3 months
−23.4%
6 months
−36.2%
YTD
−95.7%
1 year
−95.7%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has GOSS performed since 02/2019?

$10,000 grew to $75 by 20 Nov 2026, which is −46.7% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is GOSS?

Volatility was 85.2% per year, measured on monthly returns. The largest decline from a peak was −99.6%, with the low in 10/2026.

How does GOSS compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.6% per year at 16.1% volatility, GOSS returned −46.7% at 85.2%. The correlation of monthly returns was 0.28; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Gossamer Bio, Inc. (GOSS): Return and risk | Portfolio Lab